Overview
Availability
- Associate Professor David Wyld is:
- Available for supervision
Works
Search Professor David Wyld’s works on UQ eSpace
2014
Conference Publication
Pathologic response of rectal adenocarcinoma to preoperative long course chemoradiotherapy (Lccrt). An assessment at a tertiary referral hospital
Christie, Hayden, Burge, Matthew, Eastgate, Melissa and Wyld, David (2014). Pathologic response of rectal adenocarcinoma to preoperative long course chemoradiotherapy (Lccrt). An assessment at a tertiary referral hospital. COSA's 41st Annual Scientific Meeting. Joining Forces - Accelerating Progress, Melbourne, Australia, 2-4 December, 2014. Chichester, West Sussex, United Kingdom: Wiley-Blackwell Publishing. doi: 10.1111/ajco.12305
2013
Journal Article
The median informs the message: accuracy of individualized scenarios for survival time based on oncologists' estimates
Kiely, Belinda E., Martin, Andrew J., Tattersall, Martin H. N., Nowak, Anna K., Goldstein, David, Wilcken, Nicholas R. C., Wyld, David K., Abdi, Ehtesham A., Glasgow, Amanda, Beale, Philip J., Jefford, Michael, Glare, Paul A. and Stockler, Martin R. (2013). The median informs the message: accuracy of individualized scenarios for survival time based on oncologists' estimates. Journal of Clinical Oncology, 31 (28), 3565-3572. doi: 10.1200/JCO.2012.44.7821
2013
Journal Article
Patterns of chemotherapy treatment for women with invasive epithelial ovarian cancer - A population-based study
Jordan, S., Steer, C., DeFazio, A., Quinn, M., Obermair, A., Friedlander, M., Francis, J., O'Brien, S., Goss, G., Wyld, D. and Webb, P. (2013). Patterns of chemotherapy treatment for women with invasive epithelial ovarian cancer - A population-based study. Gynecologic Oncology, 129 (2), 310-317. doi: 10.1016/j.ygyno.2013.02.007
2013
Conference Publication
Pancreatic cancer patient's moderate or high unmet supportive care needs over time and risk factors of future unmet needs
Beesley, Vanessa L., Janda, Monika, Wockner, Leesa F., O'Rourke, Peter, Gooden, Helen, Goldstein, David, Merrett, Neil D., Wyld, David K. and Neale, Rachel E. (2013). Pancreatic cancer patient's moderate or high unmet supportive care needs over time and risk factors of future unmet needs. COSA's 40th Annual Scientific Meeting. Cancer Care Coming of Age, Adelaide Convention Centre, Adelaide, SA Australia, 12-14 November 2013. Chichester, West Sussex, United Kingdom: Wiley-Blackwell Publishing.
2012
Conference Publication
Pulmonary Embolism in Medical Oncology Patients: Symptomatic Versus Incidental
Thaker, D. A., Blazak, J., Wyld, D., Steinke, K., Hughes, B. and Burge, M. (2012). Pulmonary Embolism in Medical Oncology Patients: Symptomatic Versus Incidental. HOBOKEN: WILEY-BLACKWELL.
2012
Journal Article
Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial
Neoptolemos, John P., Moore, Malcolm J., Cox, Trevor F., Valle, Juan W., Palmer, Daniel H., McDonald, Alexander C., Carter, Ross, Tebbutt, Niall C., Dervenis, Christos, Smith, David, Glimelius, Bengt, Charnley, Richard M., Lacaine, François, Scarfe, Andrew G., Middleton, Mark R., Anthoney, Alan, Ghaneh, Paula, Halloran, Christopher M., Lerch, Markus M., Oláh, Attila, Rawcliffe, Charlotte L., Verbeke, Caroline S., Campbell, Fiona, Büchler, Markus W., European Study Group for Pancreatic Cancer and Wyld, David (2012). Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial. JAMA, 308 (2), 147-56. doi: 10.1001/jama.2012.7352
2012
Journal Article
Breast Cancer Risk and 6q22.33: Combined Results from Breast Cancer Association Consortium and Consortium of Investigators on Modifiers of BRCA1/2
Kirchhoff, Tomas, Gaudet, Mia M., Antoniou, Antonis C., McGuffog, Lesley, Humphreys, Manjeet K., Dunning, Alison M., Bojesen, Stig E., Nordestgaard, Borge G., Flyger, Henrik, Kang, Daehee, Yoo, Keun-Young, Noh, Dong-Young, Ahn, Sei-Hyun, Dork, Thilo, Schuermann, Peter, Karstens, Johann H., Hillemanns, Peter, Couch, Fergus J., Olson, Janet, Vachon, Celine, Wang, Xianshu, Cox, Angela, Brock, Ian, Elliott, Graeme, Reed, Malcolm W. R., Burwinkel, Barbara, Meindl, Alfons, Brauch, Hiltrud, Hamann, Ute ... Wyld, David (2012). Breast Cancer Risk and 6q22.33: Combined Results from Breast Cancer Association Consortium and Consortium of Investigators on Modifiers of BRCA1/2. Plos One, 7 (6) e35706, e35706-1-e35706-10. doi: 10.1371/journal.pone.0035706
2012
Conference Publication
Usefulness of medical oncologists' estimates of survival time in people with advanced cancer
Kiely, Belinda E., Martin, Andrew J., Tattersall, Martin H. N., Nowak, Anna K., Goldstein, David, Wilcken, Nicholas, Wyld, David, Beale, Philip James, Jefford, Michael, Glasgow, Amanda L., Abdi, Ehtesham A., Glare, Paul A. and Stockler, Martin R. (2012). Usefulness of medical oncologists' estimates of survival time in people with advanced cancer. 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, IL USA, 1-6 June 2012. Alexandria, VA USA: American Society of Clinical Oncology.
2012
Conference Publication
Safety of bevacizumab used in routine practice in patients with metastatic colorectal cancer
Dzienis, M., Malczewski, A., Goh, J., Hughes, B., Eastgate, M., Wyld, D. and Burge, M. (2012). Safety of bevacizumab used in routine practice in patients with metastatic colorectal cancer. Medical Oncology Group of Australia Incorporated Annual Scientific Meeting, Program and Abstracts: Targeting Cancer from Diagnosis to Cure & 5th Annual COGNO Annual Scientific Meeting, Brisbane, QLD Australia, 8-10 August 2012. Wiley-Blackwell Publishing.
2012
Journal Article
The advantage of letrozole over tamoxifen in the BIG 1-98 trial is consistent in younger postmenopausal women and in those with chemotherapy-induced menopause
Chirgwin, Jacquie, Sun, Zhuoxin, Smith, Ian, Price, Karen N., Thuerlimann, Beat, Ejlertsen, Bent, Bonnefoi, Herve, Regan, Meredith M., Goldhirsch, Aron, Coates, Alan S., International Breast Cancer Study Group (IBCSG) and Wyld, David (2012). The advantage of letrozole over tamoxifen in the BIG 1-98 trial is consistent in younger postmenopausal women and in those with chemotherapy-induced menopause. Breast Cancer Research and Treatment, 131 (1), 295-306. doi: 10.1007/s10549-011-1741-6
2012
Conference Publication
Analysis of plasma biomarkers potentially associated with antiangiogenic resistance in NCIC CTG/AGITG CO.20: A phase III randomized trial of cetuximab (CET) plus either brivanib alaninate (BRIV) or placebo in patients (pts) with chemotherapy refractory, k
Shapiro, Jeremy David, Siu, Lillian L., O'Callaghan. Christopher J., Zalcberg, John Raymond, Moore, Malcolm J., Price, Timothy Jay, Doyle, Catherine, Simes, John, Findlay, Brian Peter, Cronk, Michelle F., Shaikh, Asif, Joubert, Warren Lance, Samson, Benoit, Bonaventura, Antonino, Underhill, Craig, Wyld, David, Walters, Ian B., Phillips, Penny, Tu, Dongsheng and Jonker, Derek J. (2012). Analysis of plasma biomarkers potentially associated with antiangiogenic resistance in NCIC CTG/AGITG CO.20: A phase III randomized trial of cetuximab (CET) plus either brivanib alaninate (BRIV) or placebo in patients (pts) with chemotherapy refractory, k. 2012 ASCO Annual Meeting, Chicago Il, United States, 01-05 June 2012. Alexandria, VA United States: American Society of Clinical Oncology.
2012
Conference Publication
Treatment of metastatic neuroendocrine tumours with (Lu)-L-177-octreotate: experience at Royal Brisbane and Women's Hospital
Sharma, A., Burge, M., MacFarlane, D., McDade, H., Kemp, S. and Wyld, D. (2012). Treatment of metastatic neuroendocrine tumours with (Lu)-L-177-octreotate: experience at Royal Brisbane and Women's Hospital. Medical Oncology Group of Australia Incorporated Annual Scientific Meeting, Program and Abstracts: Targeting Cancer from Diagnosis to Cure & 5th Annual COGNO Annual Scientific Meeting , Brisbane, QLD, Australia, 8 – 10 August 2012. Chichester, West Sussex, United Kingdom: Wiley-Blackwell Publishing.
2011
Journal Article
Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study
Pavel, Marianne E., Hainsworth, John D., Baudin, Eric, Peeters, Marc, Hörsch, Dieter, Winkler, Robert E., Klimovsky, Judith, Lebwohl, David, Jehl, Valentine, Wolin, Edward M., Öberg, Kjell, Van Cutsem, Eric, Yao, James C., RADIANT-2 Study Group and Wyld, D. (2011). Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. The Lancet, 378 (9808), 2005-2012. doi: 10.1016/S0140-6736(11)61742-X
2011
Journal Article
Safety, feasibility and effects of an individualised walking intervention for women undergoing chemotherapy for ovarian cancer: A pilot study
Newton, Melissa J ., Hayes, Sandi C., Janda, Monika, Webb, Penelope M., Obermair, Andreas, Eakin, Elizabeth G., Wyld, David, Gordon, Louisa G. and Beesley, Vanessa L. (2011). Safety, feasibility and effects of an individualised walking intervention for women undergoing chemotherapy for ovarian cancer: A pilot study. BMC Cancer, 11 (1) 389, 389-1-389-9. doi: 10.1186/1471-2407-11-389
2011
Journal Article
Interpreting Breast International Group (BIG) 1-98: a randomized, double-blind, phase III trial comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive, early breast cancer
Regan, Meredith M, Price, Karen N, Giobbie-Hurder, Anita, Thürlimann, Beat, Gelber, Richard D, International Breast Cancer Study Group and BIG 1-98 Collaborative Group, Colosimo, M., Cheuk, R., Kenny, L., McCarthy, N. and Wyld, D. (2011). Interpreting Breast International Group (BIG) 1-98: a randomized, double-blind, phase III trial comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive, early breast cancer. Breast cancer research : BCR, 13 (3) 209, 209. doi: 10.1186/bcr2837
2011
Journal Article
Prospective, non-randomized phase 2 clinical trial of carboplatin plus paclitaxel with sequential radical pelvic radiotherapy for uterine papillary serous carcinoma
Obermair, Andreas, Mileshkin, Linda, Bolz, Katharina, Kondalsamy-Chennakesavan, Srinivas, Cheuk, Robyn, Vasey, Paul, Wyld, David, Goh, Jeffrey, Nicklin, James L., Perrin, Lewis C., Sykes, Peter and Janda, Monika (2011). Prospective, non-randomized phase 2 clinical trial of carboplatin plus paclitaxel with sequential radical pelvic radiotherapy for uterine papillary serous carcinoma. Gynecologic Oncology, 120 (2), 179-184. doi: 10.1016/j.ygyno.2010.10.039
2011
Conference Publication
Does the addition of FDG-PET to the standard pre-operative work up of pancreatic cancer change management - a prospective study
Burge, M., Houston, K. E., Francesconi, A., O'Rourke, N., Lee, J., Macfarlane, D., Wyld, D., Hopkins, G., Finch, R. and Nathanson, L. (2011). Does the addition of FDG-PET to the standard pre-operative work up of pancreatic cancer change management - a prospective study. European Multidisciplinary Cancer Congress on Integrating Basic and Translational Science, Surgery, Radiotherapy, Medical oncology, Advocacy and Care, Stockholm, Sweden, 23 - 27 September 2011. Elsevier: Oxford, United Kingdom.
2010
Journal Article
Ranked importance of outcomes of first-line versus repeated chemotherapy among ovarian cancer patients
Beesley, Vanessa L., Clavarino, Alexandra M., Webb, Penelope M., Wyld, David K., Francesconi, Alessandra B., Horwood, Keith R., Doecke, James D., Loos, Colleen A. and Green, Adele C. (2010). Ranked importance of outcomes of first-line versus repeated chemotherapy among ovarian cancer patients. Supportive Care in Cancer, 18 (8), 943-949. doi: 10.1007/s00520-009-0734-z
2010
Journal Article
Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent
Lickliter, J. D., Francesconi, A. B., Smith, G., Burge, M., Coulthard, A., Rose, S., Griffin, M., Milne, R., McCarron, J., Yeadon, T., Wilks, A., Cubitt, A., Wyld, D. K. and Vasey, P. A. (2010). Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent. British Journal of Cancer, 103 (5), 597-606. doi: 10.1038/sj.bjc.6605841
2010
Journal Article
Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: Results of the Australasian Gastrointestinal Trials Group randomized phase III MAX study
Tebbutt, Niall C., Wilson, Kate, Gebski, Val J., Cummins, Michelle M., Zannino, Diana, Van Hazel, Guy A., Robinson, Bridget, Broad, Adam, Ganju, Vinod, Ackland, Stephen P., Forgeson, Garry, Cunningham, David, Saunders, Mark P., Stockler, Martin R., Chua, Yujo, Zalcberg, John R., Simes, R. John, Price, Timothy J., Price, Tim, Simes, John, Coates, Alan, O'Connell, Diane, Brown, Chris, Hague, Wendy, France, Alyson, Hicks, Sian, James, Rebecca, Masson, Ruby, O'Connell, Rachel ... Gebbie, Chantal (2010). Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: Results of the Australasian Gastrointestinal Trials Group randomized phase III MAX study. Journal of Clinical Oncology, 28 (19), 3191-3198. doi: 10.1200/JCO.2009.27.7723
Supervision
Availability
- Associate Professor David Wyld is:
- Available for supervision
Before you email them, read our advice on how to contact a supervisor.
Supervision history
Current supervision
-
Doctor Philosophy
Examining real-world evidence for immune checkpoint inhibitor (PD-L1) treatment in advanced non small cell lung cancer (NSCLC): A population based data analysis in Queensland, Australia
Associate Advisor
Other advisors: Professor Jason Pole
Completed supervision
-
2020
Master Philosophy
Predictors of dosimetry and outcome to peptide receptor radionuclide therapy in metastatic neuroendocrine tumour.
Principal Advisor
Other advisors: Associate Professor David Pattison
-
2021
Doctor Philosophy
Targeting receptor activator of NF-kB pathways in combination immunotherapy
Associate Advisor
Media
Enquiries
For media enquiries about Associate Professor David Wyld's areas of expertise, story ideas and help finding experts, contact our Media team: